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Summary
Primary ciliary dyskinesia (PCD) is a rare, hereditary, mul-
tiorgan disease caused by defects in the structure and
function of motile cilia. It results in a wide range of clinical
manifestations, most commonly in the upper and lower air-
ways. Central data collection in national and international
registries is essential to studying the epidemiology of rare
diseases and filling in gaps in knowledge of diseases such
as PCD. For this reason, the Swiss Primary Ciliary Dysk-
inesia Registry (CH-PCD) was founded in 2013 as a col-
laborative project between epidemiologists and adult and
paediatric pulmonologists. We describe the objectives and
methodology of the CH-PCD, present initial results, and
give an overview of current and ongoing projects.
The registry records patients of any age, suffering from
PCD, who are treated and resident in Switzerland. It col-
lects information from patients identified through physi-
cians, diagnostic facilities and patient organisations. The
registry dataset contains data on diagnostic evaluations,
lung function, microbiology and imaging, symptoms, treat-
ments and hospitalisations.
By May 2018, CH-PCD has contacted 566 physicians of
different specialties and identified 134 patients with PCD.
At present, this number represents an overall 1 in 63,000
prevalence of people diagnosed with PCD in Switzerland.
Prevalence differs by age and region; it is highest in chil-
dren and adults younger than 30 years, and in Espace Mit-
telland. The median age of patients in the registry is 25
years (range 5–73), and 41 patients have a definite PCD
diagnosis based on recent international guidelines. Data
from CH-PCD are contributed to international collaborative
studies and the registry facilitates patient identification for
nested studies.
CH-PCD has proven to be a valuable research tool that al-
ready has highlighted weaknesses in PCD clinical practice
in Switzerland.
Trial registration number: NCT03606200
Keywords: primary ciliary dyskinesia, Swiss Primary Cil-
iary Dyskinesia Registry, orphan diseases, patient reg-
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Introduction
Primary ciliary dyskinesia (PCD) is a rare, hereditary, mul-
tiorgan disease. Genetic mutations cause defects in the
structure and function of motile cilia that result in a wide
range of clinical manifestations [1]. In the upper and lower
airways, impaired mucociliary clearance leads to recurrent
and chronic infections such as rhinosinusitis, otitis, chronic
wet cough and pneumonia, and subsequently to more se-
vere manifestations in many patients, which include ir-
reversible lung damage, bronchiectasis and hearing im-
pairment [2–5]. Cilia play an important role in organ
placement in utero, and about half of PCD patients present
with situs inversus, whereas 10% have other laterality de-
fects (situs ambiguous) [6]. More rarely, about 5% of pa-
tients have simple or complex cardiovascular malforma-
tions [7]. Other organ systems that may be affected in
patients with PCD include the reproductive system, with
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many male patients reporting infertility because of im-
motile or dysfunctional sperm. In women, the fallopian
tubes are lined with ciliated cells that play a role in the
transport of gametes and embryos; thus some female pa-
tients with PCD report fertility problems such as ectopic
pregnancies. Other organs can be affected, and hydro-
cephalus, retinitis pigmentosa, and renal cysts have been
occasionally reported.
Research in PCD, as in other rare diseases, faces chal-
lenges. Currently, 39 genes have been found to be asso-
ciated with the disease in 65 to 70% of patients [8]. In
spite of increasing understanding of its genetic basis and
knowledge about PCD, the disease has no dedicated code
in the International Classification of Diseases revision 10
(ICD-10). Otherwise routine epidemiological data such as
PCD mortality and hospitalisations are therefore unavail-
able. Additionally, PCD is difficult to diagnose. A single,
standard diagnostic test is lacking [9], and thus diagnosis
of PCD requires a combination of tests, some of which
require high expertise, that are based on evidence-based
guidelines [9, 10].
Despite advances in PCD diagnostics, many patients are
still misdiagnosed or diagnosed late in life so prevalence is
not accurately known. The prevalence of PCD is estimated
to be around 1 in 10,000, but the figure varies considerably
between studies [1]. This is an unavoidable product of low
numbers. Even large hospitals care for few PCD patients,
and single-centre studies have small sample sizes. In many
countries, care is decentralised and differs between coun-
tries – or even within the same country. In Switzerland, we
found that most clinics care for fewer than three PCD pa-
tients [11].
Centralised collection of data in national and international
registries is essential to raising patient numbers in the epi-
demiological study of rare diseases such as PCD, and fill-
ing in gaps in knowledge. Centralised data collection al-
lows comparison and standardisation of care, and study of
the long-term prognosis and quality of life of PCD patients.
Thus CH-PCD was founded in 2013 as a collaborative pro-
ject between epidemiologists and adult and paediatric pul-
monologists. Beginning as a pilot project in the canton of
Bern, CH-PCD was extended in 2014 to include all regions
of Switzerland. The data centre of CH-PCD is located at
the Institute of Social and Preventive Medicine (ISPM) at
the University of Bern and contributes data to the inter-
national PCD registry [12] and other international studies,
such as the international PCD (iPCD) cohort [13].
Here we describe the objectives and methodology of the
CH-PCD, present initial results, and give an overview of
current and ongoing projects.
Objectives of the Swiss PCD Registry
CH-PCD collects information on diagnosis, symptoms,
treatment and follow-up of patients with PCD in Switzer-
land, and provides data for national and international mon-
itoring and research. In particular, it aims to
– Identify all patients diagnosed with PCD in Switzerland
– Collect population-based data: incidence, prevalence,
time and regional trends
– Document diagnostic evaluations, treatments, and par-
ticipation in clinical trials
– Document the clinical course of PCD, quality of life,
morbidity, and mortality
– Establish a research platform for clinical, epidemiolog-
ical, and basic research
Materials and methods
Study design
CH-PCD is a patient registry (clinicaltrials.gov registration
number: NCT03606200). At baseline, when a patient is in-
cluded in the registry, it retrospectively collects all avail-
able data since birth and then follows patients until death
or loss to follow up, collecting prospective data at regular
intervals.
Study population
CH-PCD registers Swiss residents of any age who have
PCD. Since PCD diagnostics have evolved through the
years, CH-PCD includes patients diagnosed in different
ways. For some patients, the diagnosis is based on a com-
bination of tests in accordance with current recommenda-
tions [10, 14], whereas diagnosis of others can be based
solely on strong clinical suspicion and will need to be
confirmed when the diagnostic algorithm is completed or
when improved diagnostic methods become available.
Patient identification procedures
The CH-PCD collects information from patients identified
by physicians, diagnostic facilities, patient organisations
such as the Kartagener Syndrom und Primäre Ciliäre
Dyskinesie e.V. (http://www.kartagener-syndrom.org/),
and the Swiss group for Interstitial and Orphan Lung dis-
eases (the SIOLD Registry, http://www.siold.ch). The CH-
PCD team identifies physicians working in specialties re-
lated to PCD management – particularly paediatric and
adult pulmonologists, otolaryngologists (ENT specialists),
and fertility specialists – in hospitals, clinics, and private
practices. We contact them by email, send them the study
information, and ask whether they treat any PCD patients
(fig. 1). Those who do not reply receive phone calls. Physi-
cians who report PCD patients receive a baseline reporting
form, which inquires about the information necessary to
identify and contact the patient (name, address, date of
birth, date and type of diagnosis, and last date of follow-
up). Patients thus identified are contacted by their physi-
cian or, at the physician’s request, by the CH-PCD team di-
rectly. In the first case, the physician provides and explains
the study information and an informed consent form, at the
next follow-up appointment. When the ISPM team con-
tacts the patient directly, these documents are sent by post.
Study information and consent forms are available in three
languages (French, German, and Italian).
Data sources
Detailed data are collected from patients who give in-
formed consent or assent, upon reception of the patient reg-
istration form (fig. 1). The CH-PCD team makes an ap-
pointment with the physician for data collection. At the
time of inclusion in the registry, the following documents
are thoroughly searched for any retrospectively available
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relevant information: referral letters, discharge letters, pa-
per and electronic medical charts, lung function measure-
ments, laboratory results, imaging and diagnostic tests,
drug prescriptions, physiotherapy prescriptions, and
surgery reports. After inclusion in the registry, further in-
formation from routine follow-up visits and data related
to emergency visits and hospitalizations are collected
prospectively from the same sources at yearly intervals.
What data are collected
CH-PCD collects information on demographic character-
istics such as age and sex, diagnostic tests and clinical
data about manifestations and management of the disease.
It regularly collects follow-up data on growth, lung func-
tion, clinical manifestations from all affected organ sys-
tems, microbiology, imaging, laboratory test results, ther-
apeutic interventions including surgery and physiotherapy,
and hospitalisations. It also collects information on neona-
tal symptoms related to the disease and on the symptoms
that led to referral and PCD diagnosis. Table 1 contains a
detailed overview of the data CH-PCD collects.
Ethical approval / data protection
In 2013, CH-PCD obtained special registry permission
from the Expert Committee for Professional Secrecy in
Medical Research of the Federal Office of Public Health
(FOPH). After the new Human Research Act came into
effect in Switzerland, CH-PCD obtained an authorisation
from the Cantonal Ethics Committee of Bern in 2015
(KEK-BE: 060/2015). The authorisation is valid for data
collection all over Switzerland and includes the retrospec-
tive registration of data from deceased patients and patients
lost to follow-up. For patients lost to follow-up, the reg-
istry collects basic data and last known address. Addresses
are updated in a uniform way by contacting community
registration offices, and as soon as current addresses of pa-
tients are found patients are contacted, informed and asked
for consent. Patient data are collected at hospitals, clinics,
and in private practices, and any additional patient infor-
mation is handled via post or a secure e-mail address (spc-
dr@hin.ch). Data are collected by the CH-PCD team us-
ing a local copy of the database stored on an external hard
drive with strong encryption (AES 256). In the event pho-
tocopies of data are made, they are destroyed after the da-
ta have been entered into the CH-PCD database. Personal
Figure 1: Schematic chart of patient identification and data collection for the Swiss PCD registry.
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information (names and addresses) is kept strictly separate
from the clinical information of the CH-PCD database and
is stored in a separate database.
The web-based clinical database uses Research Electronic
Data Capture (REDCap) developed at Vanderbilt Universi-
ty (Nashville, TN, USA) [15]. REDCap supports all neces-
sary security requirements, is widely used in the academic
research community, and allows data extraction in various
formats as well as linkage with international PCD research
projects such as the iPCD cohort. Access to the ISPM serv-
er and the CH-PCD database is restricted to selected per-
sons working on the registry. Data in paper form are se-
curely locked and can only accessed by the CH-PCD team.
Daily, weekly and monthly back-ups are performed and se-
curely stored on the ISPM servers.
Data quality and analyses
CH-PCD data from each patient are manually checked
for completeness, plausibility and consistency. Ambigui-
ties are resolved in collaboration with treating physicians
at the time of data collection or after the manual quality
check. Data extractions for embedded national or inter-
national studies are routinely checked for quality assur-
ance. Basic data on patient identification, calculated dis-
ease prevalence and characteristics of included patients
are presented in the annual CH-PCD report and sent to
all collaborating physicians and patient organisations. For
each planned analysis, eligible data are validated and
anonymized. For national analyses, CH-PCD data are
analysed at ISPM Bern. Data are also contributed to inter-
national collaborative analyses. Since not all patients have
diagnostic information that is up to current standards, all
analyses are stratified by level of diagnostic certainty. Ap-
propriate statistical methods are selected based on the re-
search question and all statistical analyses are performed
using STATA and R.
Funding
The setting up of CH-PCD (salaries, consumables, equip-
ment) was funded by several Swiss funding bodies that in-
clude the Lung Leagues of Bern, St Gallen, Vaud, Ticino
and Valais, and the Kantonalbernischer Hilfsbund. PCD
research at ISPM Bern is funded by the Swiss National
Science foundation (SNF 320030_173044). CH-PCD also
participates in the EU funded BEAT-PCD COST Action
(BM1407) [16, 17].
Results
Patient identification
A special effort has been made to contact all paediatric
and adult pulmonologists, otolaryngologists and fertility
specialists in the cantons of Appenzell Ausserrhoden, Ap-
penzell Innerrhoden, Basel-Landschaft, Basel-Stadt, Bern,
Fribourg, Glarus, Graubünden, Jura, Neuchâtel,
Schaffhausen, St Gallen, Thurgau, Ticino, Valais, Vaud and
Zürich. An additional effort to contact physicians from oth-
er specialties such as cardiology and ophthalmology, who
may treat rarer extrapulmonary manifestations of PCD pa-
tients, as well specialists in neonatology and radiology
who may have been involved in management of patients
began in the canton of Bern in spring 2018. Among the 566
physicians contacted by May 2018, 418 (74%) responded
to confirm whether they had or had not managed patients
with PCD. The response rate was higher among adult and
paediatric pulmonologists and ENT specialists, who are
more involved in disease management (table 2). The physi-
cian respondents identified 134 patients who were regis-
tered in CH-PCD. Three patients refused consent and were
Table 1: Description of data collected in the Swiss PCD registry.
Type of data Collected variables Data collection
1. General information Patient demographic data date of birth, sex, ethnicity, date of last follow up, date last known alive) and infor-
mation related to registration and treating physicians (date of informed consent, current and past treating
physicians)
Cross-sectional
2. Diagnostics Diagnostic status of PCD, date of diagnosis, dates, and results of diagnostics test performed (nNO testing,
VM, EM, genetic testing) and dates and results of tests performed to exclude other diagnoses (cystic fibrosis
tests)
Longitudinal
4. Clinical manifestation lead-
ing to diagnosis
Information on past symptoms and signs from the upper and lower airways (cough, upper and lower respirato-
ry infections, hearing impairment) and other systems (laterality defects, congenital heart defects, brain cilia
dysfunction, retinitis pigmentosa, renal problems, fertility problems) from the referral letters for diagnostic eval-
uation
Cross-sectional
5. Neonatal period Birth somatometric measurements, symptoms and signs of neonatal period (neonatal respiratory distress syn-
drome, neonatal cough, neonatal rhinitis), need for intensive care and ventilation
Cross-sectional
6. Growth and lung function Lung function date, somatometric measurements, spirometric measurements, other lung function tests (body
plethysmography, breath washout)
Longitudinal
7. Clinical manifestations Date of clinical visit, information on upper and lower respiratory symptoms and signs (cough, upper and lower
respiratory infections, hearing impairment) and symptoms and signs from other affected systems (laterality de-
fects, congenital heart defects, fertility problems) and active or passive smoking during the follow-up period
since last visit
Longitudinal
8. Therapy Date of prescription, information on inhaled and nasal medication (bronchodilators, inhaled corticosteroids,
nasal sprays), antibiotics prescription, oxygen therapy, mechanical ventilation, physiotherapy and vaccinations
Longitudinal
9. Hospitalisations and surgi-
cal interventions
Information on hospitalisation (clinic, reason for hospitalisation, diagnosis, date of discharge), date and type of
surgery
Longitudinal
10. Microbiology Date of microbiology examination, type of sample, and isolated bacteria Longitudinal
11. Imaging Date and findings of chest and sinus imaging (X-Ray, CT, and MRI), information on location of the findings and
information on other types of imaging
Longitudinal
12. Other tests Date and results of other performed tests (blood gas tests, atopy tests) Longitudinal
13. Family history Number of siblings, PCD affected siblings and other family members, patient ID of PCD affected family mem-
bers, and relationship of affected family members
Cross-sectional
nNO = nasal nitric oxide; VM = videomicroscopy; EM = electron microscopy; CT = computed tomography; MRI = magnetic resonance imaging
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not included in the registry. Detailed data have already
been collected for 78 patients. For the remaining 53 pa-
tients, basic demographic and diagnostic data are current-
ly available. The numbers of patients identified by canton
varied from 0 to 46, and most physicians reported either no
or at most five patients. Patient identification of retrospec-
tively diagnosed or newly diagnosed patients is ongoing.
Prevalence of diagnosed disease
With an assumed prevalence of 1 in 10,000 [1], 842 PCD
patients are expected to live in Switzerland (population of
8,419,550; BSF 2016). The 134 patients identified to date
result in a prevalence of 1 in 63,000 (which represents
about 1 in 6 of the expected number of Swiss PCD pa-
tients). This prevalence varied by age (fig. 2). We found a
much higher prevalence of known cases in children aged
up to 10 years (1 in 44,000), adolescents aged 11–20 (1
in 24,000), and young adults (1 in 36,000) compared with
adults older than 30 (1 in 104,000–130,000). Prevalence
also differed by geographic region (fig. 3), with most cases
treated in Espace Mittelland – the cantons of Bern, Fri-
bourg, Jura, Neuchâtel and Solothurn (prevalence 1 in
37,000), and the fewest in Ticino (prevalence 1 in
177,000).
Figure 2: Prevalence of PCD diagnosed in Switzerland by age
group, calculated by dividing the number of patients identified in
the Swiss PCD registry by the number of the people in the respec-
tive age group living in Switzerland. Prevalence is presented as
cases/100,000 inhabitants.
Characteristics of the study population
Table 3 summarises the basic characteristics of the 131 pa-
tients currently included in CH-PCD. Their median age is
25 years (range 5–73) and 51% are male. Four patients
have died, one at the age of 45 from multi-organ failure
following acute appendicitis and one at the age of 66 from
acute respiratory failure. Date and cause of death were not
registered in the charts for the other two patients. Diagnos-
tic information was available for 92 patients, and age at di-
agnosis ranged from birth to age 54 years, with a median
age of 4.6 years. Among these 92 patients, only 41 have a
definite PCD diagnosis based on current international diag-
nostic guidelines [10] – primarily hallmark ultrastructural
defects identified by electron microscopy (EM). Twenty-
two patients were diagnosed only by low nasal NO val-
ue and/or video microscopy analysis, and the remaining 29
patients by clinical symptoms alone. Most of the patients
in these two diagnostic groups have not undergone the full
diagnostic algorithm proposed by international guidelines
[10, 18].
Current and ongoing studies with data from the Swiss
PCD Registry
CH-PCD has participated in several international studies.
It contributes Swiss data to the iPCD Cohort [13], which
has been set up under the EU-funded FP7 Project BEST-
CILIA (Better Experimental Screening and Treatment for
Primary Ciliary Dyskinesia, http://www.bestcilia.eu/). In
addition to the 131 patients from Switzerland, the iPCD
Cohort includes data from over 3700 PCD patients from 21
countries. CH-PCD patients have been included in a study
Figure 3: Prevalence of diagnosed PCD patients treated in the dif-
ferent cantons of Switzerland. The scale on the right represents
PCD cases per 100,000 inhabitants.
Table 2: Patient identification for the SPCDR: contacted physicians, response rate, and identified patients by medical specialty.
Specialty Contacted physicians Responding physicians Response rate Identified patients
Pulmonologists 152 120 79% 54
Paediatric pulmonologists 57 44 77% 75
ENT specialists 164 132 80% 3
Fertility specialists / urologists 67 41 61% 0
Cardiologists 37 23 62% 0
Ophthalmologists 37 17 46% 0
Neurologists 19 16 84% 0
Nephrologists 6 6 100% 0
Radiologists 15 9 60% 0
General paediatricians / general practitioners* 12 12 100% 2
Total 566 420 74% 134
* General paediatricians and general practitioners were not contacted systematically, but only in selected patients identified through the Kartagener Syndrom und Primäre Ciliäre
Dyskinesie e.V. patient organisation or when prompted by other physicians
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of growth and nutrition in PCD patients from 16 countries,
since chronic respiratory disease can affect growth and nu-
trition, which can influence lung function (see appendix 1)
[19]. The study found that PCD patients of all age groups
are shorter than their peers and children younger than 10
years old, and also have lower body mass index (BMI).
Results vary between countries, but height was reduced in
most participating centres. Swiss patients had height and
BMI within normal limits (fig. 4). Lung function was posi-
tively associated with height and BMI. PCD has been con-
sidered to be a relatively mild disease, especially compared
with cystic fibrosis, thus another recent study has com-
pared lung function in PCD and cystic fibrosis patients
[20].This study found that PCD patients from all countries,
including Switzerland (fig. 4), had impaired lung function
compared to normal references in all age groups (supple-
mentary material). In children and adolescents, lung func-
tion of PCD patients was similar to that of cystic fibro-
sis patients (FEV1 % predicted was 81% in PCD patients
versus 78% in cystic fibrosis patients aged 14–17 years).
Lobectomy is suggested for the management of patients
with localised bronchiectasis, so a third study (manuscript
submitted) examined the effects of lobar resection in PCD
across countries. The study showed that most lobectomised
patients have poor lung function that continues to decline
after surgery. In an effort to find ways to include more
sensitive measures of lung function in routine clinical set-
tings, another study aimed to assess alternatives to the
lung clearance index (LCI) derived from a shorter protocol
for the nitrogen multiple breath washout test [21]. All pa-
tients in CH-PCD with available multiple breath washout
measurements were included with German patients in this
study, which found a 79% prevalence of abnormal values
for LCI2.5% and 72% for the significantly shorter LCI5%.
Ongoing studies from the iPCD cohort (including CH-PCD
data) describe the evolution of PCD diagnostic methods in
Europe over the years and the neonatal manifestations in
patients with PCD [22].
CH-PCD has also provided data to the International PCD
Registry [12] and participated in the development of PCD-
specific, health-related quality of life questionnaires (QoL-
PCD). The QoL-PCD questionnaires are the first multidi-
mensional measure to assess health-related quality of life.
They were originally developed and validated in English in
four different versions for children 6–12 years old, adoles-
cents 13–17 years old, adults and parent-proxies [23–25].
We translated them into German using words and phrases
that are easily understood both in Germany and in Switzer-
land, and performed cognitive testing for the translated
questionnaires in Swiss patients of different age groups.
CH-PCD was also used to identify eligible patients for the
first multicentre randomised controlled trial in PCD (tri-
al registration: EudraCT 2013-004664-58) [26], which de-
termined the efficacy and safety of azithromycin main-
tenance therapy. Outcome measures included number of
exacerbations, lung function measured with spirometry,
body plethysmography and multiple breath washout, QoL-
Figure 4: Growth and lung function of patients participating in the Swiss PCD registry.Height (A) and BMI (B) by age group compared to na-
tional references (Braegger et al. Paediatrica. 2011;22:9–11 [32]); FEV1 (C) and FVC (D) by age group compared with GLI international refer-
ences (Quanjer et al. Eur Respir J. 2012;40:1324–43 [34]). All values are presented as mean z-scores (95% confidence intervals) after adjust-
ing for sex and level of diagnostic certainty, calculated using multivariable linear regression models.
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PCD, hearing impairment, sputum microbiology and in-
flammatory markers. The study is now concluded and re-
sults will soon be available.
Discussion
CH-PCD is one of few PCD patient registries worldwide
and the only one that actively tries to identify all patients
diagnosed in a single country (Switzerland). After contact-
ing all medical specialties that could encounter PCD pa-
tients in the largest part of Switzerland, we found (a) low
awareness of PCD among practitioners who are not adult
or paediatric pulmonologists, (b) decentralised care and di-
agnosis of the disease, and (c) low prevalence of diagnosed
PCD patients, particularly among adults.
Interpretation of results and comparison with other
studies
Nearly all patients with PCD identified in Switzerland
were reported by paediatric and adult pulmonologists
whom we contacted. The low awareness of PCD among all
other medical specialties is evident. This is understandable
for nephrologists or neurologists, but is surprising for ENT
specialists because ENT problems are as common, if not
more so, as lower respiratory problems in PCD. Because
we made special efforts to contact all ENT specialists in
the largest part of Switzerland, we would expect similar
numbers of PCD patients to the ones reported by pulmo-
nologists. We would also expect a significant number of
Table 3: Basic characteristics of PCD patients currently included in the
Swiss PCD Registry (n = 131).
n (%)
Sex
Male 67 (51)
Female 64 (49)
Vital status
Alive 119 (91)
Dead 4 (3)
Lost to follow-up / moved abroad 8 (6)
Current age (n = 127)*
0–9 years 18 (14)
10–19 years 33 (26)
20–29 years 28 (22)
30–39 years 14 (11)
40–49 years 12 (10)
≥50 years 22 (17)
Laterality status
Situs solitus 50 (38)
Situs inversus 37 (28)
Heterotaxia 4 (3)
Information missing/not yet collected 40 (31)
Diagnostic information (n = 92)
Definite PCD diagnosis† 41 (45)
Possible PCD diagnosis‡ 22 (24)
Clinical diagnosis only 29 (32)
Age at diagnosis (n = 92)§ 4.6 (0–54)
Data are presented as n (%) unless stated
* As of May 2018, excluding the four deceased patients
† Defined as hallmark PCD electron microscopy findings and/or bial-
lelic gene mutation identified based on the European Respiratory So-
ciety PCD Diagnostics Task Force guidelines
‡Abnormal light or high-frequency video microscopy finding and/or
low (≤77 nl.min−1) nasal nitric oxide value
§ In years, presented as median and range
Diagnostic information and age at diagnosis were available for 92 pa-
tients
patients reported by fertility specialists as 50% of male
PCD patients have been reported to be infertile and many
females also report fertility problems [27]. This striking
difference between expected and reported numbers indi-
cates that many PCD patients remain undiagnosed and are
managed symptomatically by other medical specialties. In
addition to low awareness, our data have confirmed that
the management of PCD in Switzerland is decentralised
and most physicians treat small numbers of patients.
The registry data confirm an earlier European study that
found that children with PCD in Switzerland were treated
in 17 centres (8 of which are tertiary) with 1 to 5 patients
treated per centre [11]. In contrast to cystic fibrosis, which
is treated in a few recognised centres, Switzerland has no
recognised PCD centres, although the disease is even rar-
er, and many patients are managed by private practition-
ers. It is unclear how this affects the care of PCD patients
in Switzerland. Even more importantly, PCD diagnosis is
decentralised and Switzerland does not yet have designat-
ed diagnostic centres that perform all or at least most of
the recommended diagnostic tests. This contrasts with oth-
er countries with one national PCD centre, such as Den-
mark, or a collaborative diagnostic network of centres as
in the UK [28]. The lack of designated diagnostic centres
could explain why fewer than half of the patients identi-
fied had a definite diagnosis based on international recom-
mendations. The diagnoses of some patients were based
only on clinical manifestations, while in others diagnosis
was based on nasal NO measurement alone, which can
have low positive predictive value, or on video microscopy
analysis on a single occasion instead of the recommended
three samples, analysed in different occasions.
Reported prevalence of PCD varies importantly between
studies. In a survey of the European Respiratory Taskforce
(ERS TF) sent to all centres treating children with PCD,
Switzerland had a prevalence of 1 in 20,000 among chil-
dren aged 5–14 years, one of the highest among participat-
ing countries [29]. Our CH-PCD data suggest a prevalence
of 1 in 27,000 for the age group of 5–14 years, but much
lower prevalence of known cases for patients older than
30 years. The higher prevalence of disease diagnosed in
adolescents aged 10–20 years compared with children aged
0–10 years and young adults aged 20–30 years suggests
that most PCD patients are diagnosed late. We have made
every effort to contact all of the physicians who might care
for patients with PCD in most of Switzerland. Based on the
low prevalence of disease diagnosed in adults older than
30 years, we conclude that a large proportion of adult pa-
tients with PCD are not yet diagnosed. Most older adults
with PCD could have not been diagnosed as children be-
cause at the time PCD was poorly understood and aware-
ness of the disease was even lower. Our data suggest that
these patients are also not diagnosed in adulthood; other-
wise, the numbers of adult patients included in the registry
should be much higher than the number of paediatric pa-
tients. This observation is in accordance with international
data from the iPCD cohort and other available studies [13,
30] suggesting that PCD was for many years considered
a paediatric disease. Also, some adult pulmonologists be-
lieve that diagnosis of PCD would not change the manage-
ment of their “non-cystic fibrosis bronchiectasis” patients,
and they are therefore less diligent in following diagnos-
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tic guidelines. A third possibility for the small numbers of
diagnosed adults could be increased mortality from PCD
in adulthood. However, data on PCD mortality is lacking
worldwide, and in our experience the severity of disease is
highly variable but in adults it is generally less severe than
cystic fibrosis [5, 30, 31].
Strengths and limitations
The biggest strength of CH-PCD is the thorough method-
ology for patient identification, registration, and standard-
ised data collection. We actively contact all physicians who
might be involved in the management of patients with PCD
using a uniform process. We also collaborate closely with
a national network of clinical and diagnostic collaborators
and advisors, and with the Swiss PCD patient organization.
We present regular updates in national meetings and annu-
al reports. The CH-PCD database allows data sharing and
linking with international PCD projects such as the interna-
tional PCD registry and the iPCD cohort (with high-level
measures taken for data protection). The main limitation of
the registry is that at time of patient registration, data col-
lection is retrospective, which might lead to inconsistent
and missing information for some patients. The CH-PCD
team tries whenever possible to clarify these issues in com-
munication with the treating physicians.
Future implications for clinical management and re-
search
The data from CH-PCD underline the current weaknesses
of diagnosis and management of PCD in Switzerland. In
the coming years, we need to increase the effort to raise the
awareness of all physicians involved in the care of PCD,
including nonrespiratory specialists. CH-PCD will contin-
ue to contact physicians nationwide from all specialties
that are relevant to PCD, not only to identify patients but
also to inform them about the disease. CH-PCD activities
and research results will be broadly presented in local and
national meetings and conferences, and in both scientific
and lay publications. At the same time, we need to catch up
with the current international standards of PCD diagnosis
and management and prioritise the establishment of cen-
tralised reference centres. Efforts are currently underway
to establish a designated diagnostic centre at the Universi-
ty of Bern. Diagnostic approaches need to be updated and
new patients should follow the available diagnostic algo-
rithms [10]. Older patients should also benefit from recent
diagnostic advances and should be invited to be retested
whenever needed [30]. These efforts and advances should
be communicated to the government and policymakers to
allow health policies to be updated because, among other
things, getting disability insurance for PCD in Switzerland
is at present allowed only via diagnosis by EM analysis.
In an effort to improve prospective data collection, we de-
veloped adult and parent-proxy version versions of a stan-
dardised PCD follow-up form and a patient symptom ques-
tionnaire in collaboration with an international group of
PCD experts including pulmonologists, paediatric pulmo-
nologists, ENT specialists, diagnostic scientists, epidemi-
ologists, study nurses, and physiotherapists [16]. The fol-
low-up form includes key questions on diagnostic tests,
signs and symptoms, clinical tests and treatments. It con-
sists of several modules, including a more extensive mod-
ule to be used at baseline and several shorter ones for
regular follow-up visits. The follow-up form and the ques-
tionnaires are available in English, German, and French,
and are currently being piloted in PCD clinics in countries
using one of these languages.
In summary
CH-PCD is now established in Switzerland and PCD pa-
tient identification is ongoing. This article highlights the
value of the registry as a research tool in national and in-
ternational collaborative studies and the need to improve
clinical practice in Switzerland.
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Appendix 1
Supplementary material
Height, BMI and lung function data of patients includ-
ed in the CH-PCD
Data on height, BMI and lung function of patients included
in the CH-PCD were included in publications of the in-
ternational PCD (iPCD) cohort on these topics [1a, 2a].
Details of the methodology were described in the publica-
tions.
Data preparation
We checked data quality to identify outliers and implausi-
ble values, and contacted physicians when necessary to re-
solve any such matters.
We calculated age- and sex-adjusted height and BMI z-
scores, based on national reference values [3a]. Growth
references available for height and BMI were intended for
persons up to 19 years of age. For patients aged <20 years,
we calculated height and BMI z-scores, based on the exact
age-specific references. For older patients, we calculated
height and BMI z-scores, based on the reference values
for 19-year-olds, because no growth z-score references
presently exist for adults.
We calculated FEV1 and FVC z-scores adjusted for age,
sex, height and ethnicity using the GLI 2012 reference val-
ues [4a]. We excluded data from children who were aged
<6 years to ensure better measurement quality.
Statistical analysis
We compared height and BMI z-scores and FEV1 and FVC
z-scores of the PCD patients to the reference values, us-
ing mixed linear regression models with a fixed intercept
(difference to reference population), and random intercept
to account for repeated measurements of the same patient.
In addition, to identify the determinants of height and BMI
and of lung function, we included fixed effects for sex, age
group and diagnostic certainty in the models.
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